Investigation of pulmonary gas exchange efficacy usually requires arterial blood gas analysis (aBGA) to determine arterial partial pressure of oxygen (mPaO) and compute the Riley alveolar-to-arterial oxygen difference (A-aDO); that is a demanding and invasive procedure. A noninvasive approach (AGM100), allowing the calculation of PaO (cPaO) derived from pulse oximetry (SpO), has been developed, but this has not been validated in a large cohort of chronic obstructive pulmonary disease (COPD) patients. Our aim was to conduct a validation study of the AG100 in hypoxemic moderate-to-severe COPD.
View Article and Find Full Text PDF